A 6-week, open-label, randomised, multicentre, phase IIIb, parallel-group study to compare the safety and efficacy of rosuvastatin 40 mg and rosuvastatin 40 mg in combination with ezetimibe 10 mg in subjects with hypercholesterolaemia and coronary heart disease (CHD) or atherosclerosis or a CHD risk equivalent (10-year risk score of greater than 20%)
Latest Information Update: 22 Jul 2006
At a glance
- Drugs Ezetimibe (Primary) ; Rosuvastatin (Primary)
- Indications Cardiovascular disorders; Hypercholesterolaemia; Lipid metabolism disorders
- Focus Therapeutic Use
- Acronyms EXPLORER
- Sponsors AstraZeneca
- 22 Jul 2006 Status change
- 28 Mar 2006 New trial record.